Our technology provides a unique mode of action for treating metabolic disorders, by stimulating the β2 -adrenergic receptor in a novel manner. This activation induces an altered signaling profile, leading to systemic effects without undesirable side-effects. Together with an innovative team of medicinal chemists, we design, synthesize and continuously develop novel patentable molecules, building a library of compounds to be able to fully comprehend the uniqueness and possibilities of this targeted signaling.
With our novel compounds, we are breaking paradigms, enabling chronic treatment with β2 adrenoceptor agonists, something that has so far been impossible due to side effects and receptor desensitization. For the first time, the full beneficial aspects of β2 adrenoceptor agonists can be leveraged for the treatment of metabolic disorders.
With restoration of insulin sensitivity and glucose tolerance, we can potentially reverse type 2 diabetes. And a powerful effect on fat mass, that is ensuring a healthy weight loss phenotype, coupled with an increased metabolism, makes for a completive alternative to patients with obesity.
This new concept brought to life by our novel compounds can be applied to many other diseases, enabling the broadening of our focus into metabolic disorders as well as muscular wasting disorders.
Curiosity is what drives me. I’ve dedicated most of my career to identifying a new treatment for type 2 diabetes. We’ve never been closer to a solution that could revolutionize the treatment not only of diabetes, but obesity too.
Prof. Tore Bengtsson
Founder and CSO
